Heather L. McArthur, MD, MPH - Chair's Take on Harnessing the Immune System in the Treatment of TNBC and Beyond: Where Are We Now and Where Are We Going Next?

Chia sẻ

Manage episode 271557622 series 1118501
Thông tin tác giả PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education được phát hiện bởi Player FM và cộng đồng của chúng tôi - bản quyền thuộc sở hữu của nhà sản xuất (publisher), không thuộc về Player FM, và audio được phát trực tiếp từ máy chủ của họ. Bạn chỉ cần nhấn nút Theo dõi (Subscribe) để nhận thông tin cập nhật từ Player FM, hoặc dán URL feed vào các ứng dụng podcast khác.
Go online to PeerView.com/KFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Dr. Heather McArthur provides a brief recap of how the emergence of checkpoint inhibitor therapy in TNBC has changed the management of this challenging subtype of breast cancer, and what some of the unanswered questions and controversies are that ongoing research is aiming to answer. Upon completion of this activity, participants should be better able to: Discuss the rationale for use of cancer immunotherapies in the treatment of triple-negative breast cancer (TNBC) specifically and breast cancer more broadly, Assess efficacy, safety, and other key data from clinical trials assessing immunotherapies and immune-based combinations throughout the continuum of TNBC, including in metastatic settings as well as in early-stage disease in neoadjuvant or adjuvant settings, and relevant implications for clinical practice, Evaluate the current and emerging role of immunotherapies in TNBC, nuances of patient selection and treatment integration, biomarker testing when relevant, management of immune-related adverse events, and other practical aspects related to their use in clinical practice, Integrate immune checkpoint inhibitors into treatment plans of patients with TNBC based on latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, and patient needs/preferences.

195 tập